[S02DA03, antipyrine, Cholestyramine can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EC02, sulfadiazine, Cholestyramine can cause a decrease in the absorption of Sulfadiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01ED01, sulfadimethoxine, Cholestyramine can cause a decrease in the absorption of Sulfadimethoxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07AB03, sulfaguanidine, Cholestyramine can cause a decrease in the absorption of Sulfaguanidine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01ED02, sulfalene, Cholestyramine can cause a decrease in the absorption of Sulfametopyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01ED07, sulfamerazine, Cholestyramine can cause a decrease in the absorption of Sulfamerazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EB03, sulfamethazine, Cholestyramine can cause a decrease in the absorption of Sulfamethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AB01, sulfamethizole, Cholestyramine can cause a decrease in the absorption of Sulfamethizole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EC01, sulfamethoxazole, Cholestyramine can cause a decrease in the absorption of Sulfamethoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01ED05, sulfamethoxypyridazine, Cholestyramine can cause a decrease in the absorption of Sulfamethoxypyridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EC03, sulfamoxole, Cholestyramine can cause a decrease in the absorption of Sulfamoxole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EB04, sulfapyridine, Cholestyramine can cause a decrease in the absorption of Sulfapyridine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EB01, sulfisomidine, Cholestyramine can cause a decrease in the absorption of Sulfaisodimidine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AB02, sulfisoxazole, Cholestyramine can cause a decrease in the absorption of Sulfisoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AB02, sulindac, Cholestyramine can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BC01, glymidine, Cholestyramine can cause a decrease in the absorption of Glymidine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AX04, apazone, Cholestyramine can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA02, tetracycline, Cholestyramine can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA21, tolmetin, Cholestyramine can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BA05, triamcinolone, Cholestyramine may increase the excretion rate of Triamcinolone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, Cholestyramine can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D07AC02, fluclorolone, Cholestyramine may increase the excretion rate of Fluclorolone which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA07, mometasone, Cholestyramine may increase the excretion rate of Mometasone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA28, vancomycin, The therapeutic efficacy of Vancomycin can be decreased when used in combination with Cholestyramine.]
[B01AA03, warfarin, Cholestyramine can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03BA10, xipamide, Cholestyramine can cause a decrease in the absorption of Xipamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC01, vemurafenib, Cholestyramine can cause a decrease in the absorption of Vemurafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H05BX03, doxercalciferol, The serum concentration of Doxercalciferol can be decreased when it is combined with Cholestyramine.]
[G03AC10, drospirenone, Cholestyramine can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA01, aspirin, Cholestyramine can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A11CC03, alfacalcidol, The serum concentration of Alfacalcidol can be decreased when it is combined with Cholestyramine.]
[H02AB11, prednylidene, Cholestyramine may increase the excretion rate of Prednylidene which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA31, teriflunomide, Cholestyramine may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA01, aldosterone, Cholestyramine may increase the excretion rate of Aldosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX05, regorafenib, Cholestyramine can cause a decrease in the absorption of Regorafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01AA01, acetyldigitoxin, Cholestyramine can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AX12, lomitapide, Cholestyramine can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03AA01, bendroflumethiazide, Cholestyramine can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA10, benorilate, Cholestyramine can cause a decrease in the absorption of Benorilate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H03AA04, tiratricol, Cholestyramine can cause a decrease in the absorption of Tiratricol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AH01, celecoxib, Cholestyramine can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R02AX03, benzydamine, Cholestyramine can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A05AA03, cholic acid, Cholestyramine can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AP05, simeprevir, Cholestyramine can cause a decrease in the absorption of Simeprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03BA03, betamethasone, Cholestyramine may increase the excretion rate of Betamethasone which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AB02, bezafibrate, Cholestyramine can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AA07, acenocoumarol, Cholestyramine can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AA01, dicumarol, Cholestyramine can cause a decrease in the absorption of Dicoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BE01, acetaminophen, Cholestyramine can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AA11, tioclomarol, Cholestyramine can cause a decrease in the absorption of Tioclomarol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Cholestyramine.]
[M02AA25, aceclofenac, Cholestyramine can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AB11, acemetacin, Cholestyramine can cause a decrease in the absorption of Acemetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01EC01, acetazolamide, Cholestyramine can cause a decrease in the absorption of Acetazolamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AE16, alminoprofen, Cholestyramine can cause a decrease in the absorption of Alminoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A05AA04, obeticholic acid, Cholestyramine can cause a decrease in the absorption of Obeticholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03CA02, bumetanide, Cholestyramine can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07EC04, balsalazide, Cholestyramine can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H05BX05, calcifediol, The serum concentration of Calcifediol can be decreased when it is combined with Cholestyramine.]
[D05AX03, calcitriol, The serum concentration of Calcitriol can be decreased when it is combined with Cholestyramine.]
[R03BA02, budesonide, Cholestyramine may increase the excretion rate of Budesonide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB07, bumadizone, Cholestyramine can cause a decrease in the absorption of Bumadizone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be decreased when it is combined with Cholestyramine.]
[J01AA14, sarecycline, Cholestyramine can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01AA15, omadacycline, Cholestyramine can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AC05, lornoxicam, Cholestyramine can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AB08, ciprofibrate, Cholestyramine can cause a decrease in the absorption of Ciprofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01AA11, clomocycline, Cholestyramine can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB14, cloprednol, Cholestyramine may increase the excretion rate of Cloprednol which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB17, cortivazol, Cholestyramine may increase the excretion rate of Cortivazol which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA09, cyclothiazide, Cholestyramine can cause a decrease in the absorption of Cyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB13, deflazacort, Cholestyramine may increase the excretion rate of Deflazacort which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB05, demegestone, Cholestyramine can cause a decrease in the absorption of Demegestone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03AC09, desogestrel, Cholestyramine can cause a decrease in the absorption of Desogestrel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01XA12, dexpanthenol, The serum concentration of Dexpanthenol can be decreased when it is combined with Cholestyramine.]
[G03DB08, dienogest, Cholestyramine can cause a decrease in the absorption of Dienogest resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AH02, rofecoxib, Cholestyramine can cause a decrease in the absorption of Rofecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D07XB03, fluprednidene, Cholestyramine may increase the excretion rate of Fluprednidene which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC04, droxicam, Cholestyramine can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA27, dexketoprofen, Cholestyramine can cause a decrease in the absorption of Dexketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03AA04, chlorothiazide, Cholestyramine can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03BA04, chlorthalidone, Cholestyramine can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A11CC05, cholecalciferol, The serum concentration of Cholecalciferol can be decreased when it is combined with Cholestyramine.]
[N02BA07, ethenzamide, Cholestyramine can cause a decrease in the absorption of Ethenzamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AB08, etodolac, Cholestyramine can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA06, etofenamate, Cholestyramine can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AB09, etofibrate, Cholestyramine can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AE05, fenbufen, Cholestyramine can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Cholestyramine can cause an increase in the absorption of Ferrous sulfate anhydrous resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R03BA03, flunisolide, Cholestyramine may increase the excretion rate of Flunisolide which could result in a lower serum level and potentially a reduction in efficacy.]
[S02BA08, fluocinolone acetonide, Cholestyramine may increase the excretion rate of Fluocinolone acetonide which could result in a lower serum level and potentially a reduction in efficacy.]
[A05AX05, odevixibat, The therapeutic efficacy of Odevixibat can be decreased when used in combination with Cholestyramine.]
[M01AG01, mefenamic acid, Cholestyramine can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AB01, clofibrate, Cholestyramine can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B06AX04, mitapivat, Cholestyramine can cause a decrease in the absorption of Mitapivat resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03BA03, clopamide, Cholestyramine can cause a decrease in the absorption of Clopamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AX13, proquazone, Cholestyramine can cause a decrease in the absorption of Proquazone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA13, leflunomide, Cholestyramine may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA16, imidazole-2-hydroxybenzoate, Cholestyramine can cause a decrease in the absorption of Imidazole salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R03BA08, ciclesonide, Cholestyramine may increase the excretion rate of Ciclesonide which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC10, indobufen, Cholestyramine can cause a decrease in the absorption of Indobufen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AH03, valdecoxib, Cholestyramine can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01AA06, lanatoside C, Cholestyramine can cause a decrease in the absorption of Lanatoside C resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BA03, cortisone, Cholestyramine may increase the excretion rate of Cortisone which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB09, lonazolac, Cholestyramine can cause a decrease in the absorption of Lonazolac resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA31, loxoprofen, Cholestyramine can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB15, meprednisone, Cholestyramine may increase the excretion rate of Meprednisone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, Cholestyramine can cause a decrease in the absorption of Cyclopenthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AA07, rosuvastatin, Cholestyramine can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA02, mofebutazone, Cholestyramine can cause a decrease in the absorption of Mofebutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AX22, morniflumate, Cholestyramine can cause a decrease in the absorption of Morniflumate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AH05, etoricoxib, Cholestyramine can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AX01, nabumetone, Cholestyramine can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01AA01, demeclocycline, Cholestyramine can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07EC03, olsalazine, Cholestyramine can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01AA07, deslanoside, Cholestyramine can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D07XC02, desoximetasone, Cholestyramine may increase the excretion rate of Desoximetasone which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA03, desoxycorticosterone, Cholestyramine may increase the excretion rate of Desoxycortone which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE12, oxaprozin, Cholestyramine can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03BA01, dexamethasone, Cholestyramine may increase the excretion rate of Dexamethasone which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, Cholestyramine can cause a decrease in the absorption of Diazoxide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01EC02, dichlorphenamide, Cholestyramine can cause a decrease in the absorption of Diclofenamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC03, diclofenac, Cholestyramine can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07AB02, phthalylsulfathiazole, Cholestyramine can cause a decrease in the absorption of Phthalylsulfathiazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03CA03, piretanide, Cholestyramine can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D07XC04, diflucortolone, Cholestyramine may increase the excretion rate of Difluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA11, diflunisal, Cholestyramine can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01AA04, digitoxin, Cholestyramine can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01AA05, digoxin, The serum concentration of Digoxin can be decreased when it is combined with Cholestyramine.]
[C10AX09, ezetimibe, Cholestyramine can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A11CC02, dihydrotachysterol, The serum concentration of Dihydrotachysterol can be decreased when it is combined with Cholestyramine.]
[D07AC18, prednicarbate, Cholestyramine may increase the excretion rate of Prednicarbate which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, Cholestyramine can cause a decrease in the absorption of Propyphenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AB14, proglumetacin, Cholestyramine can cause a decrease in the absorption of Proglumetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC05, ketorolac, Cholestyramine can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA06, salsalate, Cholestyramine can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01AA02, doxycycline, Cholestyramine can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AA01, simvastatin, Cholestyramine can cause a decrease in the absorption of Simvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07AB04, succinylsulfathiazole, Cholestyramine can cause a decrease in the absorption of Succinylsulfathiazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02CC01, sumatriptan, Cholestyramine can cause a decrease in the absorption of Sumatriptan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H01AA01, corticotropin, Cholestyramine may increase the excretion rate of Corticotropin which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, Cholestyramine can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AG02, tolfenamic acid, Cholestyramine can cause a decrease in the absorption of Tolfenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03CA04, torsemide, Cholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02CA01, trilostane, Cholestyramine may increase the excretion rate of Trilostane which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB04, zomepirac, Cholestyramine can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX15, zonisamide, Cholestyramine can cause a decrease in the absorption of Zonisamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A11CC01, ergocalciferol, The serum concentration of Ergocalciferol can be decreased when it is combined with Cholestyramine.]
[G03CA03, estradiol, Cholestyramine can cause a decrease in the absorption of Estradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R03BA09, fluticasone furoate, Cholestyramine may increase the excretion rate of Fluticasone furoate which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA05, fluticasone, Cholestyramine may increase the excretion rate of Fluticasone which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA04, fluvastatin, The serum concentration of Fluvastatin can be decreased when it is combined with Cholestyramine.]
[L02AA03, ethinyl estradiol, Cholestyramine can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AC06, meloxicam, The serum concentration of Meloxicam can be decreased when it is combined with Cholestyramine.]
[C10AA03, pravastatin, Cholestyramine can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D11AX24, deoxycholic acid, Cholestyramine can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AE04, fenoprofen, Cholestyramine can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BG04, floctafenine, Cholestyramine can cause a decrease in the absorption of Floctafenine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AA02, fludrocortisone, Cholestyramine may increase the excretion rate of Fludrocortisone which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XB01, flumethasone, Cholestyramine may increase the excretion rate of Flumethasone which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC08, fluocinonide, Cholestyramine may increase the excretion rate of Fluocinonide which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB03, fluocortolone, Cholestyramine may increase the excretion rate of Fluocortolone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01CB05, fluorometholone, Cholestyramine may increase the excretion rate of Fluorometholone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, Cholestyramine can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AE10, darunavir, Cholestyramine can cause a decrease in the absorption of Darunavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03CA01, furosemide, Cholestyramine can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AB04, gemfibrozil, Cholestyramine can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03XA02, gestrinone, Cholestyramine can cause a decrease in the absorption of Gestrinone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H01AB01, thyrotropin alfa, Cholestyramine can cause a decrease in the absorption of Thyrotropin alfa resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AA12, fluindione, Cholestyramine can cause a decrease in the absorption of Fluindione resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07EC02, mesalamine, Cholestyramine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA26, nimesulide, Cholestyramine can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03AA03, hydrochlorothiazide, Cholestyramine can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S02BA01, hydrocortisone, Cholestyramine may increase the excretion rate of Hydrocortisone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA02, hydroflumethiazide, Cholestyramine can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R02AX02, ibuprofen, Cholestyramine can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R01AD07, tixocortol, Cholestyramine may increase the excretion rate of Tixocortol which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, Cholestyramine can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC01, indomethacin, Cholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AA06, cerivastatin, Cholestyramine can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03BA02, quinethazone, Cholestyramine can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA10, ketoprofen, Cholestyramine can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AC03, deferasirox, Cholestyramine can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AE11, tiaprofenic acid, Cholestyramine can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03AD01, levonorgestrel, Cholestyramine can cause a decrease in the absorption of Levonorgestrel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AA02, lovastatin, Cholestyramine can cause a decrease in the absorption of Lovastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01AA04, lymecycline, Cholestyramine can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DC03, lynestrenol, Cholestyramine can cause a decrease in the absorption of Lynestrenol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA18, meclofenamic acid, Cholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be decreased when it is combined with Cholestyramine.]
[C03BA05, mefruside, Cholestyramine can cause a decrease in the absorption of Mefruside resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AA01, mephobarbital, Cholestyramine can cause a decrease in the absorption of Methylphenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01AA05, methacycline, Cholestyramine can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01EC05, methazolamide, Cholestyramine can cause a decrease in the absorption of Methazolamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AX03, methotrexate, Cholestyramine may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA08, methyclothiazide, Cholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB04, methylprednisolone, Cholestyramine may increase the excretion rate of Methylprednisolone which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC14, methylprednisolone aceponate, Cholestyramine may increase the excretion rate of Methylprednisolone aceponate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, Cholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BB03, aminopyrine, Cholestyramine can cause a decrease in the absorption of Aminophenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03XB01, mifepristone, Cholestyramine can cause a decrease in the absorption of Mifepristone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01AA08, minocycline, Cholestyramine can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01BD01, amiodarone, The serum concentration of Amiodarone can be decreased when it is combined with Cholestyramine.]
[L04AA06, mycophenolic acid, Cholestyramine may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XC01, raloxifene, Cholestyramine can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA12, naproxen, Cholestyramine can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H05BX02, paricalcitol, The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine.]
[C10AD02, niacin, Cholestyramine can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA17, niflumic acid, Cholestyramine can cause a decrease in the absorption of Niflumic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DC02, norethindrone, Cholestyramine can cause a decrease in the absorption of Norethisterone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03AC07, norgestrienone, Cholestyramine can cause a decrease in the absorption of Norgestrienone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C02KX01, bosentan, Cholestyramine can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04CA02, tamsulosin, Cholestyramine can cause a decrease in the absorption of Tamsulosin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01AC01, ouabain, Cholestyramine can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC02, oxyphenbutazone, Cholestyramine can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AA04, oxytetracycline, Cholestyramine can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DB06, chlormadinone, Cholestyramine can cause a decrease in the absorption of Chlormadinone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB05, paramethasone, Cholestyramine may increase the excretion rate of Paramethasone which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA02, phenindione, Cholestyramine can cause a decrease in the absorption of Phenindione resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AA02, phenobarbital, Cholestyramine can cause a decrease in the absorption of Phenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AA04, phenprocoumon, Cholestyramine can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA01, phenylbutazone, Cholestyramine can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AB02, phenytoin, Cholestyramine can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AA05, atorvastatin, Cholestyramine can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC06, piroxicam, Cholestyramine can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BG02, rosiglitazone, The serum concentration of Rosiglitazone can be decreased when it is combined with Cholestyramine.]
[C03AA05, polythiazide, Cholestyramine can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AA08, pitavastatin, Cholestyramine can cause a decrease in the absorption of Pitavastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03BA02, prednisolone, Cholestyramine may increase the excretion rate of Prednisolone which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB07, prednisone, Cholestyramine may increase the excretion rate of Prednisone which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA03, primidone, Cholestyramine can cause a decrease in the absorption of Primidone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M04AB01, probenecid, Cholestyramine can cause a decrease in the absorption of Probenecid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C10AB05, fenofibrate, Cholestyramine can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AA05, propranolol, Cholestyramine can cause a decrease in the absorption of Propranolol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01AB01, proscillaridin, Cholestyramine can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA05, salicylamide, Cholestyramine can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07EC01, sulfasalazine, Cholestyramine can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC08, salicylic acid, Cholestyramine can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia and metabolic acidosis can be increased when Cholestyramine is combined with Spironolactone.]
[A05AA01, chenodeoxycholic acid, Cholestyramine can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[D07AB02, hydrocortisone butyrate, Cholestyramine may increase the excretion rate of Hydrocortisone butyrate which could result in a lower serum level and potentially a reduction in efficacy.]
[A05AA02, ursodiol, Cholestyramine can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
